## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: SHAI et al

Application No.: '09/367,714

Filed: January 14, 2000

'**JUN** 2 1 2000

TECH CENTER 1600/2900

1 5 2000

Art Unit: 1653

Examiner: D. Lukton

Washington, D.C.

RECEIVED JUN 19 2000

Atty.'s Docket: SHAI=2 Date: June 15, 2000

OR

OR

**BEC**H CENTER 1600/29**00** 

THE COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

WITH SEQUENCE LISTING REQUIREMENTS AND DISK Transmitted herewith is a [XX] ] Amendment [ ] RESPONSE TO NO in the above-identified application.

Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted

A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

ANTIPATHOGENIC SYNTHETIC PEPTIDES AND COMPOSITIONS COMPRISING

No additional fee is required. [xx]

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS		
TOTAL	*	MINUS	** 20	0		
INDEP.	*	MINUS	*** 3	0		
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						

	RATE	ADDITIONAL FEE
х	9	\$
х	39	\$
+	130	\$
NAL FEE TOTAL		\$

SMALL ENTITY

OTHER THAN SMALL ENTITY ADDITIONAL RATE FEE 18 \$ \$ 78 \$ 260 TOTAL

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

ADDITIO

Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

	Small Entity	Other Than Small Entity		
	Response Filed Within	Response Filed Within		
	[ ] First - \$ 55.00	[ ] First - \$ 110.00		
	[ ] Second - \$ 190.00	[ ] Second - \$ 380.00		
	{ } Third - \$ 435.00	[ ] Third - \$ 870.00		
	[ ] Fourth - \$ 680.00	[ ] Fourth - \$ 1360.00		
	Month After Time Period Set	Month After Time Period Set		
1	[ ] Less fees (\$) already paid for month(s) extension  Please charge my Deposit Account No. 02-4035 in the amount of \$			
1	A check in the amount of \$ is attached (check no	_).		
(X)	The Commissioner is hereby authorized and requested to charge a overpayment to Deposit Account No. 02-4035. This authorization a			

nection with this application or credit any associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

**BROWDY AND NEIMARK** 

Attorneys for Applicant(s)

ALLEN C. YUN Registration No. 37,971

(202) 737-3528 Facsimile: Telephone: (202) 628-5197

(X)

JUN 1 5 2000

09/367714

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):	for
This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	l
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other:	
Applicant Must Provide:	
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.	
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For questions regarding compliance to these requirements, please contact:	
For Rules Interpretation, call (703) 308-4216	
For CRF Submission Help, call (703) 308-4212	
For Patentin software help, call (703) 308-6856	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE